IV Dosage of Hyoscine Butylbromide
The standard intravenous dose of hyoscine butylbromide for adults is 20 mg administered as a single slow IV injection, which can be repeated after 30 minutes if needed, with a maximum of 100 mg per day.
Adult Dosing
The evidence base for IV hyoscine butylbromide dosing comes primarily from clinical research rather than formal guidelines. For adults, administer 20 mg IV as a single dose 1, 2, 3, 4. This can be given as a slow intravenous injection.
Repeat Dosing
- May repeat the 20 mg dose after 30 minutes if symptoms persist
- Maximum daily dose: 100 mg (5 doses)
- The drug demonstrates dose-dependent effects, with 20 mg showing superior efficacy compared to lower doses of 5 mg or 10 mg in clinical studies 2
Clinical Context by Indication
For antisialagogue effects (reducing secretions):
- 10 mg IV was found to be the optimal dose balancing efficacy and side effects 1
- 5 mg was insufficient for adequate secretion control
- 20 mg achieved better drying but caused more tachycardia 1
For gastrointestinal spasm/pain:
- 20 mg IV is the standard dose 3, 4, 5
- Onset of action is rapid when given intravenously
- Duration of effect is relatively short (30-60 minutes)
Pediatric Dosing
No established pediatric IV dosing guidelines exist in the provided evidence. The pediatric emergency drug guidelines 6 do not include hyoscine butylbromide, indicating it is not a standard pediatric emergency medication. Use in children should be approached with extreme caution and only when specifically indicated, with dosing extrapolated from adult data based on weight.
Important Precautions and Contraindications
Cardiovascular Effects
- Causes dose-dependent tachycardia 7, 1
- Unlike atropine, hyoscine butylbromide produces only tachycardia without initial bradycardia 7
- The drug acts as both a muscarinic antagonist and ganglion blocker 7
Administration Technique
- Administer as a SLOW IV injection 8
- Rapid administration may exacerbate cardiovascular effects
Special Populations
Myasthenia Gravis:
- Traditionally concerning due to anticholinergic effects
- However, case report evidence suggests it may be used cautiously as it did not exacerbate myasthenic symptoms 9
- The quaternary ammonium structure limits CNS penetration
Common Adverse Events
- Mild adverse events occurred in 75% of patients receiving the drug versus 57% with placebo 3
- Most common: tachycardia, dry mouth, blurred vision
- Generally well-tolerated with no serious adverse events reported in clinical trials 3, 4, 5
Clinical Efficacy Considerations
Important caveat: Recent high-quality evidence shows mixed results for efficacy:
- A 2024 RCT found no significant benefit for labor augmentation 3
- A 2024 RCT found no benefit over placebo for gastroenteritis pain 5
- A 2022 RCT showed non-significant pain reduction for post-procedure cramping 4
However, the drug remains widely used and recommended in clinical guidelines for:
- Abdominal cramping pain in IBS 10
- Biliary spasm
- Diagnostic procedures requiring smooth muscle relaxation 2
Veterinary Note
The FDA-approved formulation 8 is specifically for veterinary use in horses only at a dose of 0.3 mg/kg (20 mg/mL concentration). This should not be confused with human formulations, though the concentration and dosing principles informed human use.
Human formulations typically come as 20 mg/mL in 1 mL ampoules for the 20 mg standard adult dose.